Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antirheumatic Agents | 25 | 2023 | 1368 | 4.480 |
Why?
|
Arthritis, Rheumatoid | 29 | 2023 | 3755 | 3.600 |
Why?
|
Drugs, Generic | 6 | 2020 | 448 | 2.690 |
Why?
|
Drug Prescriptions | 15 | 2021 | 1669 | 2.200 |
Why?
|
Heart Failure | 16 | 2024 | 11674 | 2.120 |
Why?
|
Medicare | 30 | 2024 | 6770 | 2.060 |
Why?
|
Angiotensin Receptor Antagonists | 6 | 2023 | 1039 | 1.910 |
Why?
|
Insurance Claim Review | 9 | 2024 | 741 | 1.610 |
Why?
|
Cohort Studies | 68 | 2024 | 41446 | 1.610 |
Why?
|
Analgesics, Opioid | 16 | 2022 | 3804 | 1.520 |
Why?
|
Medicaid | 17 | 2024 | 2818 | 1.490 |
Why?
|
Gout | 7 | 2023 | 621 | 1.360 |
Why?
|
Propensity Score | 18 | 2024 | 1908 | 1.340 |
Why?
|
United States | 87 | 2024 | 72339 | 1.320 |
Why?
|
Anemia, Sickle Cell | 3 | 2024 | 1064 | 1.310 |
Why?
|
Drug Utilization | 5 | 2020 | 1188 | 1.310 |
Why?
|
Pregnancy Complications | 18 | 2022 | 2947 | 1.300 |
Why?
|
United States Food and Drug Administration | 4 | 2024 | 1664 | 1.230 |
Why?
|
Biological Products | 9 | 2022 | 912 | 1.220 |
Why?
|
Stroke Volume | 8 | 2024 | 5497 | 1.190 |
Why?
|
Electronic Health Records | 15 | 2024 | 4811 | 1.190 |
Why?
|
Databases, Factual | 20 | 2024 | 7956 | 1.140 |
Why?
|
Product Surveillance, Postmarketing | 2 | 2024 | 452 | 1.140 |
Why?
|
Renal Dialysis | 4 | 2021 | 1797 | 1.140 |
Why?
|
Arthritis, Psoriatic | 6 | 2022 | 218 | 1.130 |
Why?
|
Tumor Necrosis Factor-alpha | 8 | 2022 | 4354 | 1.110 |
Why?
|
Allopurinol | 4 | 2021 | 198 | 1.100 |
Why?
|
Medication Errors | 4 | 2013 | 783 | 1.070 |
Why?
|
Cardiovascular Diseases | 17 | 2023 | 15498 | 0.990 |
Why?
|
Nursing Homes | 4 | 2013 | 1082 | 0.960 |
Why?
|
Venous Thromboembolism | 5 | 2021 | 1866 | 0.950 |
Why?
|
Piperidines | 4 | 2022 | 1656 | 0.920 |
Why?
|
Abnormalities, Drug-Induced | 8 | 2021 | 339 | 0.910 |
Why?
|
Immunologic Factors | 4 | 2022 | 1588 | 0.890 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2023 | 2243 | 0.860 |
Why?
|
Spironolactone | 2 | 2024 | 412 | 0.850 |
Why?
|
Research Design | 7 | 2024 | 6178 | 0.850 |
Why?
|
Computer Simulation | 8 | 2024 | 6238 | 0.850 |
Why?
|
Famotidine | 1 | 2022 | 17 | 0.830 |
Why?
|
Gout Suppressants | 3 | 2021 | 177 | 0.820 |
Why?
|
Insurance, Health | 4 | 2019 | 2497 | 0.820 |
Why?
|
Neprilysin | 2 | 2022 | 478 | 0.780 |
Why?
|
Neonatal Abstinence Syndrome | 3 | 2022 | 108 | 0.750 |
Why?
|
Humans | 157 | 2024 | 761423 | 0.740 |
Why?
|
Gastrointestinal Agents | 4 | 2022 | 510 | 0.740 |
Why?
|
Pregnancy Trimester, First | 10 | 2021 | 907 | 0.740 |
Why?
|
Patient Preference | 2 | 2019 | 924 | 0.730 |
Why?
|
Pyrimidines | 4 | 2022 | 3027 | 0.710 |
Why?
|
Aged | 62 | 2024 | 169235 | 0.710 |
Why?
|
Biphenyl Compounds | 4 | 2023 | 1007 | 0.700 |
Why?
|
Drug Recalls | 1 | 2020 | 20 | 0.690 |
Why?
|
Heart Failure, Systolic | 1 | 2021 | 135 | 0.680 |
Why?
|
Drug Utilization Review | 2 | 2018 | 248 | 0.670 |
Why?
|
Insurance, Pharmaceutical Services | 2 | 2020 | 348 | 0.670 |
Why?
|
Hyperkalemia | 1 | 2022 | 233 | 0.670 |
Why?
|
Tetrazoles | 4 | 2023 | 909 | 0.660 |
Why?
|
Natural Language Processing | 3 | 2024 | 1162 | 0.660 |
Why?
|
Drug Substitution | 2 | 2021 | 290 | 0.650 |
Why?
|
Hyperphosphatemia | 1 | 2019 | 38 | 0.650 |
Why?
|
Colitis, Ulcerative | 5 | 2022 | 1922 | 0.650 |
Why?
|
Anticoagulants | 8 | 2023 | 4813 | 0.640 |
Why?
|
Polypharmacy | 1 | 2021 | 305 | 0.640 |
Why?
|
Osteoarthritis, Knee | 2 | 2019 | 1229 | 0.630 |
Why?
|
Immunosuppressive Agents | 6 | 2024 | 4172 | 0.620 |
Why?
|
Drug Labeling | 1 | 2021 | 248 | 0.620 |
Why?
|
Female | 98 | 2024 | 392581 | 0.610 |
Why?
|
Opioid-Related Disorders | 9 | 2022 | 2162 | 0.610 |
Why?
|
Calcium Phosphates | 1 | 2019 | 171 | 0.610 |
Why?
|
Spondylitis, Ankylosing | 2 | 2016 | 152 | 0.600 |
Why?
|
Adverse Drug Reaction Reporting Systems | 3 | 2023 | 488 | 0.590 |
Why?
|
Patient Acceptance of Health Care | 3 | 2020 | 3204 | 0.590 |
Why?
|
Chelating Agents | 1 | 2019 | 387 | 0.580 |
Why?
|
Alendronate | 2 | 2021 | 175 | 0.580 |
Why?
|
Kidney Failure, Chronic | 2 | 2021 | 2471 | 0.580 |
Why?
|
Atrial Fibrillation | 7 | 2023 | 5127 | 0.570 |
Why?
|
Prospective Payment System | 1 | 2018 | 136 | 0.570 |
Why?
|
Osteoporotic Fractures | 2 | 2021 | 411 | 0.570 |
Why?
|
Bone Density Conservation Agents | 3 | 2021 | 795 | 0.560 |
Why?
|
Diabetes Mellitus, Type 2 | 7 | 2024 | 12143 | 0.550 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2020 | 3244 | 0.550 |
Why?
|
Pyrroles | 2 | 2022 | 1125 | 0.540 |
Why?
|
Male | 73 | 2024 | 360736 | 0.530 |
Why?
|
Comparative Effectiveness Research | 3 | 2018 | 709 | 0.530 |
Why?
|
Rheumatic Diseases | 2 | 2020 | 648 | 0.520 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2018 | 2751 | 0.520 |
Why?
|
Marketing | 1 | 2018 | 220 | 0.520 |
Why?
|
Hydroxychloroquine | 8 | 2022 | 426 | 0.510 |
Why?
|
Stroke | 8 | 2023 | 9756 | 0.510 |
Why?
|
Diabetic Nephropathies | 1 | 2023 | 973 | 0.510 |
Why?
|
Psoriasis | 5 | 2022 | 939 | 0.510 |
Why?
|
Treatment Outcome | 24 | 2024 | 64651 | 0.500 |
Why?
|
Medicare Part D | 1 | 2020 | 355 | 0.500 |
Why?
|
Warfarin | 3 | 2023 | 1483 | 0.490 |
Why?
|
Epidemiologic Research Design | 1 | 2018 | 368 | 0.490 |
Why?
|
Congenital Abnormalities | 2 | 2017 | 709 | 0.490 |
Why?
|
Acute Coronary Syndrome | 2 | 2018 | 2190 | 0.490 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2017 | 284 | 0.490 |
Why?
|
Arthroplasty, Replacement, Knee | 3 | 2022 | 1385 | 0.480 |
Why?
|
Data Mining | 2 | 2023 | 551 | 0.480 |
Why?
|
Osteoarthritis, Hip | 1 | 2019 | 406 | 0.480 |
Why?
|
Private Sector | 1 | 2018 | 398 | 0.480 |
Why?
|
Drug Approval | 2 | 2018 | 814 | 0.480 |
Why?
|
Epidemiologic Methods | 2 | 2017 | 1336 | 0.480 |
Why?
|
Crohn Disease | 3 | 2022 | 2279 | 0.470 |
Why?
|
Rheumatology | 2 | 2018 | 615 | 0.460 |
Why?
|
Immune System Diseases | 1 | 2016 | 257 | 0.450 |
Why?
|
Diphosphonates | 1 | 2018 | 636 | 0.440 |
Why?
|
Prenatal Exposure Delayed Effects | 5 | 2022 | 2509 | 0.430 |
Why?
|
Hip Fractures | 2 | 2018 | 988 | 0.420 |
Why?
|
Uric Acid | 2 | 2023 | 807 | 0.420 |
Why?
|
Medication Adherence | 3 | 2020 | 2176 | 0.420 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1385 | 0.420 |
Why?
|
Bone Marrow Transplantation | 1 | 2020 | 2695 | 0.420 |
Why?
|
Methadone | 1 | 2015 | 321 | 0.410 |
Why?
|
Osteoporosis | 2 | 2021 | 1605 | 0.410 |
Why?
|
Drug Combinations | 3 | 2023 | 2048 | 0.400 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12456 | 0.400 |
Why?
|
Inflammatory Bowel Diseases | 4 | 2022 | 2422 | 0.400 |
Why?
|
Middle Aged | 48 | 2024 | 220826 | 0.390 |
Why?
|
North Carolina | 4 | 2013 | 325 | 0.390 |
Why?
|
Risk Assessment | 15 | 2023 | 23990 | 0.390 |
Why?
|
Pregnancy | 29 | 2022 | 29862 | 0.390 |
Why?
|
Incidence | 14 | 2021 | 21341 | 0.390 |
Why?
|
Osteoarthritis | 1 | 2019 | 1060 | 0.380 |
Why?
|
Diabetes Mellitus | 3 | 2018 | 5840 | 0.370 |
Why?
|
Anticonvulsants | 6 | 2019 | 1906 | 0.370 |
Why?
|
Adult | 56 | 2024 | 221148 | 0.370 |
Why?
|
Aged, 80 and over | 18 | 2022 | 58956 | 0.370 |
Why?
|
Morphine | 1 | 2015 | 656 | 0.370 |
Why?
|
Azathioprine | 3 | 2024 | 354 | 0.360 |
Why?
|
Drug Therapy, Combination | 5 | 2023 | 6309 | 0.350 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2021 | 2119 | 0.350 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1924 | 0.350 |
Why?
|
Hyperlipidemias | 1 | 2015 | 771 | 0.340 |
Why?
|
Logistic Models | 8 | 2020 | 13255 | 0.340 |
Why?
|
Social Class | 1 | 2019 | 2004 | 0.340 |
Why?
|
Probenecid | 2 | 2021 | 73 | 0.340 |
Why?
|
Valine | 1 | 2011 | 408 | 0.340 |
Why?
|
Losartan | 1 | 2011 | 265 | 0.330 |
Why?
|
Venous Thrombosis | 1 | 2019 | 1303 | 0.330 |
Why?
|
Pulmonary Embolism | 2 | 2021 | 2566 | 0.330 |
Why?
|
Glucocorticoids | 2 | 2022 | 2161 | 0.330 |
Why?
|
Hospital Mortality | 2 | 2020 | 5291 | 0.330 |
Why?
|
Analgesics | 2 | 2013 | 1070 | 0.320 |
Why?
|
Sulfasalazine | 2 | 2021 | 84 | 0.320 |
Why?
|
Methotrexate | 6 | 2022 | 1718 | 0.320 |
Why?
|
Risk Factors | 24 | 2023 | 74167 | 0.310 |
Why?
|
Hospitalization | 10 | 2023 | 10718 | 0.300 |
Why?
|
Administration, Oral | 3 | 2021 | 4016 | 0.290 |
Why?
|
Joint Diseases | 1 | 2011 | 459 | 0.290 |
Why?
|
Follow-Up Studies | 10 | 2020 | 39117 | 0.290 |
Why?
|
Adrenal Cortex Hormones | 1 | 2016 | 1876 | 0.280 |
Why?
|
Health Care Costs | 1 | 2020 | 3243 | 0.270 |
Why?
|
Lithium Compounds | 2 | 2019 | 223 | 0.270 |
Why?
|
Steroids | 1 | 2011 | 929 | 0.270 |
Why?
|
Antipsychotic Agents | 5 | 2018 | 3068 | 0.270 |
Why?
|
Osteoporosis, Postmenopausal | 2 | 2021 | 396 | 0.260 |
Why?
|
Young Adult | 22 | 2024 | 59207 | 0.260 |
Why?
|
Pain | 3 | 2017 | 5071 | 0.260 |
Why?
|
Benzimidazoles | 1 | 2011 | 858 | 0.260 |
Why?
|
Delivery of Health Care | 1 | 2024 | 5335 | 0.260 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3879 | 0.260 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15838 | 0.250 |
Why?
|
Risk | 11 | 2021 | 9612 | 0.250 |
Why?
|
Vitamin D | 2 | 2022 | 3301 | 0.250 |
Why?
|
Mortality | 3 | 2021 | 2900 | 0.250 |
Why?
|
Registries | 4 | 2018 | 8223 | 0.240 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7389 | 0.240 |
Why?
|
Data Interpretation, Statistical | 3 | 2019 | 2691 | 0.240 |
Why?
|
Adolescent | 18 | 2024 | 88313 | 0.240 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2017 | 2152 | 0.240 |
Why?
|
Autoimmune Diseases | 1 | 2017 | 2248 | 0.240 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2023 | 10203 | 0.240 |
Why?
|
Prescription Drugs | 3 | 2024 | 631 | 0.240 |
Why?
|
Hemorrhage | 4 | 2023 | 3425 | 0.230 |
Why?
|
Hypertension | 6 | 2019 | 8542 | 0.230 |
Why?
|
Alzheimer Disease | 2 | 2022 | 8596 | 0.230 |
Why?
|
Pharmacoepidemiology | 2 | 2024 | 350 | 0.220 |
Why?
|
Multiple Sclerosis | 1 | 2019 | 3224 | 0.220 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2016 | 2163 | 0.220 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2022 | 10766 | 0.210 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2022 | 1517 | 0.210 |
Why?
|
Case-Control Studies | 4 | 2021 | 22168 | 0.210 |
Why?
|
Heart Failure, Diastolic | 1 | 2023 | 76 | 0.210 |
Why?
|
Comorbidity | 5 | 2020 | 10498 | 0.210 |
Why?
|
Cleft Palate | 2 | 2018 | 589 | 0.200 |
Why?
|
Sentinel Surveillance | 1 | 2024 | 290 | 0.200 |
Why?
|
Kidney | 1 | 2018 | 7049 | 0.200 |
Why?
|
Algorithms | 4 | 2024 | 14026 | 0.200 |
Why?
|
Pyrazoles | 2 | 2023 | 2007 | 0.200 |
Why?
|
Angiotensins | 1 | 2022 | 143 | 0.200 |
Why?
|
Smoking | 2 | 2016 | 9052 | 0.200 |
Why?
|
Prevalence | 8 | 2021 | 15717 | 0.200 |
Why?
|
Aminosalicylic Acid | 1 | 2021 | 20 | 0.200 |
Why?
|
Anti-Inflammatory Agents | 1 | 2011 | 1808 | 0.200 |
Why?
|
Omeprazole | 1 | 2022 | 105 | 0.200 |
Why?
|
Mycophenolic Acid | 1 | 2024 | 348 | 0.190 |
Why?
|
Cause of Death | 3 | 2021 | 3684 | 0.190 |
Why?
|
Thioglycolates | 1 | 2021 | 37 | 0.190 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5441 | 0.190 |
Why?
|
Myasthenia Gravis | 1 | 2024 | 214 | 0.190 |
Why?
|
Herpes Zoster Vaccine | 1 | 2021 | 49 | 0.190 |
Why?
|
Urate Oxidase | 1 | 2021 | 31 | 0.190 |
Why?
|
Acute Chest Syndrome | 1 | 2020 | 32 | 0.180 |
Why?
|
Immunization Schedule | 1 | 2021 | 227 | 0.180 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 311 | 0.180 |
Why?
|
Medication Therapy Management | 1 | 2021 | 130 | 0.170 |
Why?
|
Retrospective Studies | 17 | 2023 | 80582 | 0.170 |
Why?
|
Prescriptions | 3 | 2021 | 386 | 0.170 |
Why?
|
Health Expenditures | 2 | 2024 | 2366 | 0.170 |
Why?
|
Causality | 2 | 2024 | 1243 | 0.170 |
Why?
|
Pyridones | 2 | 2023 | 809 | 0.170 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2022 | 2273 | 0.170 |
Why?
|
Multivariate Analysis | 4 | 2014 | 12058 | 0.170 |
Why?
|
Infant, Newborn | 13 | 2022 | 26212 | 0.170 |
Why?
|
Toluidines | 1 | 2019 | 21 | 0.160 |
Why?
|
Crotonates | 1 | 2019 | 21 | 0.160 |
Why?
|
Herpes Zoster | 1 | 2021 | 253 | 0.160 |
Why?
|
Predictive Value of Tests | 4 | 2020 | 15262 | 0.160 |
Why?
|
Lawyers | 1 | 2019 | 38 | 0.160 |
Why?
|
Antidepressive Agents | 3 | 2017 | 2897 | 0.160 |
Why?
|
Hydroxybutyrates | 1 | 2019 | 79 | 0.160 |
Why?
|
Time Factors | 11 | 2022 | 39975 | 0.160 |
Why?
|
Glucosides | 1 | 2023 | 512 | 0.160 |
Why?
|
Sweden | 1 | 2021 | 1379 | 0.150 |
Why?
|
Ondansetron | 1 | 2018 | 95 | 0.150 |
Why?
|
Therapeutic Equivalency | 1 | 2018 | 134 | 0.150 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 737 | 0.150 |
Why?
|
Sertraline | 1 | 2019 | 209 | 0.150 |
Why?
|
Proton Pump Inhibitors | 1 | 2022 | 531 | 0.140 |
Why?
|
Medical Record Linkage | 1 | 2018 | 285 | 0.140 |
Why?
|
Age Distribution | 2 | 2014 | 2880 | 0.140 |
Why?
|
Antiemetics | 1 | 2018 | 186 | 0.140 |
Why?
|
Preoperative Period | 1 | 2019 | 552 | 0.140 |
Why?
|
Geography | 1 | 2019 | 656 | 0.140 |
Why?
|
Postoperative Complications | 1 | 2019 | 15650 | 0.140 |
Why?
|
Carcinoma, Basal Cell | 1 | 2022 | 560 | 0.140 |
Why?
|
Amphetamine | 1 | 2017 | 224 | 0.140 |
Why?
|
Penicillamine | 1 | 2016 | 60 | 0.130 |
Why?
|
Benzhydryl Compounds | 1 | 2023 | 916 | 0.130 |
Why?
|
Quality of Health Care | 1 | 2011 | 4330 | 0.130 |
Why?
|
Drug Repositioning | 1 | 2018 | 233 | 0.130 |
Why?
|
Citalopram | 1 | 2019 | 402 | 0.130 |
Why?
|
Opportunistic Infections | 1 | 2019 | 376 | 0.130 |
Why?
|
Nausea | 1 | 2018 | 679 | 0.130 |
Why?
|
Hypoglycemic Agents | 2 | 2022 | 3081 | 0.130 |
Why?
|
Investments | 1 | 2017 | 147 | 0.130 |
Why?
|
Serologic Tests | 1 | 2017 | 382 | 0.130 |
Why?
|
Hyperuricemia | 1 | 2018 | 222 | 0.130 |
Why?
|
Lung Diseases, Interstitial | 2 | 2021 | 917 | 0.130 |
Why?
|
Triazoles | 1 | 2021 | 903 | 0.120 |
Why?
|
Polyethylene Glycols | 1 | 2021 | 1188 | 0.120 |
Why?
|
Back Pain | 1 | 2019 | 545 | 0.120 |
Why?
|
Minocycline | 1 | 2016 | 169 | 0.120 |
Why?
|
Persistent Fetal Circulation Syndrome | 1 | 2015 | 80 | 0.120 |
Why?
|
Pre-Eclampsia | 3 | 2020 | 1231 | 0.120 |
Why?
|
Bradycardia | 1 | 2016 | 299 | 0.120 |
Why?
|
Child | 7 | 2024 | 80162 | 0.120 |
Why?
|
Cost-Benefit Analysis | 2 | 2018 | 5492 | 0.120 |
Why?
|
Sensitivity and Specificity | 3 | 2020 | 14664 | 0.120 |
Why?
|
Postpartum Hemorrhage | 1 | 2018 | 271 | 0.120 |
Why?
|
Clinical Coding | 1 | 2016 | 181 | 0.120 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 26112 | 0.120 |
Why?
|
Hydrocodone | 1 | 2014 | 48 | 0.120 |
Why?
|
Cardiovascular Agents | 1 | 2020 | 840 | 0.120 |
Why?
|
Codeine | 1 | 2014 | 51 | 0.120 |
Why?
|
Pregnancy Complications, Cardiovascular | 2 | 2016 | 515 | 0.120 |
Why?
|
Influenza Vaccines | 1 | 2021 | 767 | 0.110 |
Why?
|
Heart Defects, Congenital | 4 | 2018 | 4696 | 0.110 |
Why?
|
Hepatitis B virus | 1 | 2017 | 528 | 0.110 |
Why?
|
Monte Carlo Method | 1 | 2019 | 1257 | 0.110 |
Why?
|
Infant | 4 | 2020 | 36205 | 0.110 |
Why?
|
Nitriles | 1 | 2019 | 971 | 0.110 |
Why?
|
Epidemiology | 1 | 2016 | 279 | 0.110 |
Why?
|
Methylphenidate | 1 | 2017 | 488 | 0.110 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 2218 | 0.110 |
Why?
|
Cleft Lip | 1 | 2018 | 506 | 0.110 |
Why?
|
International Classification of Diseases | 1 | 2018 | 909 | 0.110 |
Why?
|
Meta-Analysis as Topic | 1 | 2018 | 1377 | 0.110 |
Why?
|
Ticlopidine | 1 | 2017 | 730 | 0.100 |
Why?
|
Self Report | 2 | 2016 | 3724 | 0.100 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2017 | 611 | 0.100 |
Why?
|
Age Factors | 3 | 2020 | 18400 | 0.100 |
Why?
|
Adenosine | 1 | 2017 | 808 | 0.100 |
Why?
|
Neuralgia | 1 | 2019 | 614 | 0.100 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14599 | 0.100 |
Why?
|
Physicians, Primary Care | 1 | 2019 | 623 | 0.100 |
Why?
|
Drug Industry | 1 | 2018 | 788 | 0.100 |
Why?
|
Laxatives | 1 | 2012 | 92 | 0.100 |
Why?
|
Hepatitis B | 1 | 2017 | 706 | 0.100 |
Why?
|
Psychotic Disorders | 2 | 2018 | 3223 | 0.100 |
Why?
|
Premature Birth | 3 | 2020 | 1782 | 0.100 |
Why?
|
Calcium Channel Blockers | 1 | 2015 | 694 | 0.100 |
Why?
|
Ophthalmic Solutions | 1 | 2012 | 313 | 0.090 |
Why?
|
Information Storage and Retrieval | 1 | 2017 | 819 | 0.090 |
Why?
|
Models, Structural | 1 | 2011 | 341 | 0.090 |
Why?
|
Models, Statistical | 3 | 2024 | 5077 | 0.090 |
Why?
|
Bipolar Disorder | 2 | 2019 | 5091 | 0.090 |
Why?
|
Myocardial Infarction | 3 | 2022 | 11458 | 0.090 |
Why?
|
Infant, Newborn, Diseases | 1 | 2016 | 591 | 0.090 |
Why?
|
Opiate Substitution Treatment | 1 | 2015 | 444 | 0.090 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2016 | 1241 | 0.090 |
Why?
|
Mood Disorders | 1 | 2017 | 1127 | 0.090 |
Why?
|
Bayes Theorem | 1 | 2018 | 2328 | 0.090 |
Why?
|
Enzyme Inhibitors | 1 | 2021 | 3712 | 0.090 |
Why?
|
Calcinosis | 1 | 2019 | 1469 | 0.090 |
Why?
|
Health Services Research | 1 | 2018 | 1812 | 0.090 |
Why?
|
Influenza, Human | 1 | 2021 | 1521 | 0.090 |
Why?
|
Cyclophosphamide | 1 | 2016 | 2218 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4852 | 0.090 |
Why?
|
Fetal Diseases | 1 | 2015 | 913 | 0.090 |
Why?
|
Diuretics | 1 | 2012 | 610 | 0.080 |
Why?
|
Central Nervous System | 1 | 2017 | 1337 | 0.080 |
Why?
|
Maternal Exposure | 1 | 2016 | 1063 | 0.080 |
Why?
|
Sex Distribution | 1 | 2014 | 2281 | 0.080 |
Why?
|
Hypoglycemia | 1 | 2016 | 884 | 0.080 |
Why?
|
Survival Rate | 2 | 2021 | 12720 | 0.080 |
Why?
|
Double-Blind Method | 1 | 2023 | 12330 | 0.080 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2019 | 1411 | 0.080 |
Why?
|
Diabetes, Gestational | 1 | 2018 | 1248 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2760 | 0.080 |
Why?
|
Graft vs Host Disease | 1 | 2020 | 3030 | 0.070 |
Why?
|
Child, Preschool | 2 | 2020 | 42254 | 0.070 |
Why?
|
Abruptio Placentae | 2 | 2019 | 118 | 0.070 |
Why?
|
Disease Progression | 2 | 2021 | 13502 | 0.070 |
Why?
|
Linear Models | 1 | 2017 | 5869 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3418 | 0.070 |
Why?
|
Prognosis | 4 | 2022 | 29620 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 4021 | 0.070 |
Why?
|
Arthritis | 1 | 2011 | 682 | 0.070 |
Why?
|
Health Care Surveys | 1 | 2012 | 2426 | 0.060 |
Why?
|
Prospective Studies | 4 | 2024 | 54415 | 0.060 |
Why?
|
Risperidone | 2 | 2018 | 381 | 0.060 |
Why?
|
Patient Readmission | 1 | 2019 | 3269 | 0.060 |
Why?
|
Dermatologic Agents | 2 | 2019 | 313 | 0.060 |
Why?
|
Hypnotics and Sedatives | 1 | 2012 | 1179 | 0.060 |
Why?
|
Residence Characteristics | 1 | 2014 | 2092 | 0.060 |
Why?
|
Fetal Growth Retardation | 2 | 2019 | 580 | 0.060 |
Why?
|
Antimanic Agents | 2 | 2019 | 520 | 0.060 |
Why?
|
Bone Density | 1 | 2017 | 3551 | 0.060 |
Why?
|
Continuity of Patient Care | 1 | 2011 | 1069 | 0.060 |
Why?
|
Models, Biological | 1 | 2020 | 9469 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2018 | 20093 | 0.060 |
Why?
|
Melanoma | 1 | 2022 | 5709 | 0.050 |
Why?
|
Pregnancy Trimester, Third | 2 | 2015 | 583 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2022 | 5819 | 0.050 |
Why?
|
Coronary Artery Disease | 2 | 2019 | 6395 | 0.050 |
Why?
|
Seizures | 1 | 2015 | 2957 | 0.050 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 3704 | 0.050 |
Why?
|
Neoplasms | 2 | 2022 | 22164 | 0.050 |
Why?
|
Gestational Age | 2 | 2022 | 3576 | 0.050 |
Why?
|
Health Surveys | 1 | 2011 | 4059 | 0.050 |
Why?
|
Biomedical Research | 1 | 2017 | 3429 | 0.050 |
Why?
|
Primary Health Care | 1 | 2017 | 4686 | 0.050 |
Why?
|
Chronic Disease | 2 | 2017 | 9320 | 0.050 |
Why?
|
Sex Factors | 1 | 2014 | 10548 | 0.040 |
Why?
|
Ambulatory Care | 1 | 2011 | 2775 | 0.040 |
Why?
|
France | 1 | 2021 | 498 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9179 | 0.040 |
Why?
|
Deductibles and Coinsurance | 1 | 2021 | 316 | 0.040 |
Why?
|
Uricosuric Agents | 1 | 2018 | 30 | 0.040 |
Why?
|
Hepatitis B Antigens | 1 | 2017 | 38 | 0.040 |
Why?
|
Pregnancy Outcome | 2 | 2019 | 2920 | 0.040 |
Why?
|
Infant, Small for Gestational Age | 1 | 2020 | 461 | 0.040 |
Why?
|
Carbamazepine | 1 | 2018 | 224 | 0.040 |
Why?
|
Isotretinoin | 1 | 2019 | 134 | 0.040 |
Why?
|
Mental Disorders | 1 | 2017 | 6841 | 0.040 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2022 | 1111 | 0.040 |
Why?
|
Hepatitis B Antibodies | 1 | 2017 | 160 | 0.040 |
Why?
|
Drug and Narcotic Control | 1 | 2018 | 144 | 0.030 |
Why?
|
Thalidomide | 1 | 2022 | 885 | 0.030 |
Why?
|
Labetalol | 1 | 2016 | 29 | 0.030 |
Why?
|
Pregnancy Trimesters | 1 | 2017 | 197 | 0.030 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2017 | 186 | 0.030 |
Why?
|
Taiwan | 1 | 2017 | 516 | 0.030 |
Why?
|
Atenolol | 1 | 2016 | 99 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2023 | 1116 | 0.030 |
Why?
|
Metoprolol | 1 | 2016 | 90 | 0.030 |
Why?
|
Pharmaceutical Services | 1 | 2017 | 141 | 0.030 |
Why?
|
Treatment Failure | 1 | 2022 | 2642 | 0.030 |
Why?
|
Drug Costs | 1 | 2024 | 1183 | 0.030 |
Why?
|
Suicide, Attempted | 1 | 2024 | 1398 | 0.030 |
Why?
|
Budgets | 1 | 2017 | 230 | 0.030 |
Why?
|
Health Services | 1 | 2020 | 752 | 0.030 |
Why?
|
Vomiting | 1 | 2018 | 652 | 0.030 |
Why?
|
Triazines | 1 | 2017 | 311 | 0.030 |
Why?
|
Patient Simulation | 1 | 2017 | 298 | 0.030 |
Why?
|
Remission Induction | 1 | 2020 | 2395 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 495 | 0.030 |
Why?
|
Myocardial Revascularization | 1 | 2018 | 792 | 0.030 |
Why?
|
Policy | 1 | 2017 | 508 | 0.030 |
Why?
|
Delivery, Obstetric | 1 | 2020 | 940 | 0.030 |
Why?
|
Virus Diseases | 1 | 2019 | 719 | 0.030 |
Why?
|
Pregnant Women | 1 | 2017 | 566 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2017 | 856 | 0.030 |
Why?
|
Ischemic Attack, Transient | 1 | 2018 | 882 | 0.030 |
Why?
|
Pain, Postoperative | 1 | 2022 | 1737 | 0.020 |
Why?
|
Government Regulation | 1 | 2016 | 524 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2017 | 2358 | 0.020 |
Why?
|
DNA, Viral | 1 | 2017 | 2201 | 0.020 |
Why?
|
Thiazoles | 1 | 2018 | 1517 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2019 | 1393 | 0.020 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2016 | 518 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2020 | 1188 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2022 | 9535 | 0.020 |
Why?
|
Tobacco Use Disorder | 1 | 2016 | 703 | 0.020 |
Why?
|
Amyloid beta-Peptides | 1 | 2022 | 3837 | 0.020 |
Why?
|
Central Nervous System Stimulants | 1 | 2017 | 1176 | 0.020 |
Why?
|
Odds Ratio | 1 | 2021 | 9645 | 0.020 |
Why?
|
Poverty | 1 | 2020 | 2697 | 0.020 |
Why?
|
Income | 1 | 2017 | 1876 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 3687 | 0.020 |
Why?
|
Outpatients | 1 | 2016 | 1597 | 0.020 |
Why?
|
Piperazines | 1 | 2018 | 2523 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4244 | 0.020 |
Why?
|
Hepatitis C | 1 | 2016 | 1584 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2015 | 2023 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2016 | 1934 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2016 | 2092 | 0.020 |
Why?
|
Phenotype | 1 | 2022 | 16606 | 0.010 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 3204 | 0.010 |
Why?
|
Inpatients | 1 | 2016 | 2548 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2022 | 18247 | 0.010 |
Why?
|
Epilepsy | 1 | 2017 | 3290 | 0.010 |
Why?
|
Quality of Life | 1 | 2024 | 13361 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2017 | 3357 | 0.010 |
Why?
|
Anxiety | 1 | 2016 | 4572 | 0.010 |
Why?
|
Asthma | 1 | 2019 | 6211 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2016 | 4420 | 0.010 |
Why?
|
Depression | 1 | 2016 | 8122 | 0.010 |
Why?
|
Mice | 1 | 2022 | 81509 | 0.010 |
Why?
|
Animals | 1 | 2022 | 168441 | 0.010 |
Why?
|
HIV Infections | 1 | 2016 | 17347 | 0.010 |
Why?
|